BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $7,633,000 | -51.3% | 469,430 | -58.5% | 0.19% | -41.3% |
Q4 2021 | $15,659,000 | +25.6% | 1,130,578 | +30.3% | 0.32% | +35.9% |
Q3 2021 | $12,472,000 | +73.8% | 867,920 | +91.2% | 0.24% | +76.9% |
Q2 2021 | $7,178,000 | +64.2% | 453,995 | +5.6% | 0.13% | +44.1% |
Q1 2021 | $4,372,000 | – | 429,902 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |